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Abstract
Background: Cervical artery dissection is a leading cause of cerebral ischemia in young adults.
Morphological investigations have shown alterations in the extracellular matrix (ECM) of affected
vessel walls. As matrix metalloproteinases (MMP) play a central role in the regulation of the ECM,
an increased expression of these enzymes might lead to the endothelial damage in spontaneous
cervical artery dissection (sCAD). Five different DNA polymorphisms in MMP-1, -3, -9 and -12
were tested for their frequency in patients with sCAD and compared with those of a control
population.
Methods:  Blood was sampled from 70 unrelated patients presenting consecutively in the
department of neurology of the Aachen University Medical School with sCAD and from 87 control
subjects living in the same area as the patients. The MMP polymorphisms were analyzed with
hybridization probes using the LightCycler™ (Roche Diagnostics), by sequencing using the ABI 310
Genetic Analyzer (Applied Biosystems) and with the GeneScan program on a ABI 310 Genetic
Analyzer.
Results: No statistically significant differences in the allelic distribution were found between sCAD
patients and the controls.
Conclusion: Alleles of these 5 functional polymorphisms of MMPs seem not to be associated with
structural alterations in the blood vessel wall of sCAD patients. However, this does not exclude a
pathogenetic role for MMPs in sCAD via secondary factors such as cytokines that are able to induce
these enzymes in cervical blood vessel walls.
Background
Spontaneous cervical artery dissection (sCAD) is a leading
cause of cerebral ischemia in young adults [1]. The inci-
dence in the general population is estimated at 2.6 to 2.9
per 100 000 and the mean age of occurrence is 44 to 46
years [2,3]. The reason why these sCADs occur in other-
wise healthy-appearing young adults remains poorly
understood although numerous risk factors have been
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postulated such as recent infection [4], hyperhomo-
cysteinemia [5,6], low levels of α1-antitrypsin [7] and
hypertension [8]. For most factors, evidence is limited
either due to small sample size or conflicting data from
different studies [9]. Several arguments suggest a genetic
influence in sCAD [10]. Two studies reported the overall
presence of a family history of sCAD in 2% to 3% of
patients. Secondly, patients with sCAD often present with
concomitant arterial abnormalities such as fibromuscular
dysplasia or aortic root dilation. Finally, morphological
investigations have consistently shown alterations in the
extracellular matrix (ECM) of skin biopsies even in
patients without known connective tissue disorders.
Hereditary monogenic disorders such as vascular Ehlers-
Danlos syndrome are rare in sCAD [11,12]. Genetic fac-
tors might however play a role as part of a multifactorial
predisposition (eg, causing a constitutional weakness of
the vessel wall or predisposing the vessel wall to inflam-
matory processes) [10]. Matrix metalloproteinases (MMP)
are interesting candidate genes as they play a central role
in the regulation of the ECM and earlier studies in vascular
pathologies have already shown evidence for an increased
activity of MMPs in the wall of affected blood vessels in
aortic dissection [13]. In sCAD patients, a recent study
reported higher plasma levels of MMP-2 compared to
patients with an ischemic stroke from different reasons
[14]. In the present study, we therefore investigated 5 pol-
ymorphisms in the promoter region of the MMP genes
with a known increased expression rate of the correspond-
ing enzyme as possible risk factors for sCAD [15-19].
Methods
In this single centre study, blood was sampled from 70
consecutive unrelated patients who presented with sCAD
in the years 1999 to 2003 in the department of neurology
of the Aachen University Medical School. The patients
comprised 42 men and 28 women (age range 28–70
years; median 48.5 years). The diagnosis of sCAD was
based on magnetic resonance imaging angiography and/
or digital substraction angiography. Fifty-four patients
suffered a dissection of the carotid artery, 16 of the verte-
bral artery; no cases with multiple cervical artery dissec-
tions were included. Patients with known connective
tissue disorders such as Ehlers-Danlos syndrome, angio-
graphic signs of fibromuscular dysplasia or assumed trau-
matic cervical artery dissection were excluded. Eighty-
seven german caucasian control subjects of similar age
and sex distribution living in the same area as the patients
were randomly selected in the Aachen University Blood
Bank. The control group comprised 50 men and 37
women (age range 22–68 years; median 48 years). The
study was approved by the Aachen University Ethical
Committee and written consent was obtained from all
participants.
DNA was isolated from EDTA blood using the QIAamp
DNA Blood kit (Qiagen, Hilden, Germany). The MMP-1
(-1607 1G/2G) polymorphism (rs1799750) was analyzed
with hybridization probes using the LightCycler™ (Roche
Diagnostics). Primer and probes were designed by Tib
Molbiol (MMP1-Sensor: 5'-GAT TTG AGA ATA AGT CAT
AT CTT TCT AAT X, MMP1-Anker: 5'-LC Red640- TTA ACT
ACA ATT TCC TCA TCT AAG TGG C p, MMP1proS: 5'-TTC
TTA CCC TCT TGA ACT CAC ATG-3', MMP1proAS: 5'-TTC
CTC CCC TTA TGG ATT CC-3'). The MMP-3 (-1612 5A/
6A, rs3025058), -9 (-1562 C/T, rs3918242) and -12 (-82
A/G, rs2276109) polymorphisms were analyzed by
sequencing using the ABI 310 Genetic Analyzer (Applied
Biosystems) with a standard protocol. The multiallelic
(CA)n microsatellite polymorphism in the MMP-9 gene
was analyzed with the GeneScan program on a ABI 310
Genetic Analyzer (FAM-MMP9F: 5'-GAC TTG GCA GTG
GAG ACT GCG GGC A-3', MMP9R: 5'-GAC CCC ACC
CCT CCT TGA CAG GCA-3'). To avoid inconsistencies
between different runs, the 6 most common CA-repeats
were cloned, sequenced and used as an internal standard
in every run. For statistical analyses, χ2 test was used to
determine if the genotypes were in the Hardy-Weinberg
equilibrium. Odds ratio and the 95% confidence interval
were calculated to test the association of genotype and
sCAD.
Results
The results of the genetic analyses are presented in Table 1
and 2. There were no statistically significant differences
between patients and controls in the 5 polymorphisms
investigated. The genotype distributions for all polymor-
phisms were compatible with those expected from the
Hardy-Weinberg equilibrium, except for MMP-12 in
patients.
Discussion
MMPs are a family of extracellular zinc- and calcium-
dependent endopeptidases that degrade the extracellular
matrix and other extracellular proteins [20]. The 23 mam-
malian MMPs can be placed into sub-groups based on
structural similarities and substrate specificity and they
are capable of degrading virtually all extracellular pro-
teins. In the present study, 5 polymorphisms in the pro-
moter region of MMP-1, -3, -9 and -12 genes were
investigated for a possible genetic association with sCAD.
All polymorphisms lead to an increased expression of the
corresponding enzyme and might therefore lead to ECM
instability in blood vessel walls [15-19]. In an earlier
study investigating polymorphisms in the MMP-9 gene,
no differences in the allelic distribution of both polymor-
phisms were found between sCAD patients and controls
[21]. In accordance with these results, we could also not
detect statistically significant differences in overall fre-BMC Neurology 2009, 9:40 http://www.biomedcentral.com/1471-2377/9/40
Page 3 of 5
(page number not for citation purposes)
Table 1: Distribution of Genotypes and Alleles of all single nucleotide polymorphisms
Controls, No
(Frequency)
Patients, No
(Frequency)
Odds ratio
(95% confidence interval)
MMP-1 Genotype 2G/2G 22 (0.253) 15 (0.214) Reference
2G/1G 50 (0.575) 34 (0.486) 1.003
(0.456 to 2.204)
1G/1G 15 (0.172) 21 (0.3) 0.487
(0.191 to 1.237)
2G/2G 22 (0.253) 15 (0.214) Reference
1G/1G or 1G/2G 66 (0,747) 55 (0,786) 0,818
(0,39 to 1,73)
1G/1G 15 (0.172) 21 (0.3) Reference
2G/2G or 2G/1G 72 (0.828) 49 (0.7) 2,05
(0.97 to 4.38)
2G/2G or 2G/1G 72 (0.828) 49 (0.7) Reference
1G/1G 15 (0.172) 21 (0.3) 0.486
(0.23 to 1.03)
1G/1G or 1G/2G 66 (0,747) 55 (0,784) Reference
2G/2G 22 (0,253) 15 (0,214) 1,222
(0.579 to 2.581)
1G/2G 50 (0.575) 34 (0.486) Reference
2G/2G or 1G/1G 37 (0,425) 36 (0,514) 0,6989
(0.371 to 1.316)
MMP-3 Genotype 6A/6A 21 (0.242) 16 (0.228) Reference
5A/6A 47 (0.540) 34 (0.486) 0.359
(0.149 to 0.865)
5A/5A 19 (0.218) 20 (0.286) 0.724
(0.293 to 1.787)
6A/6A 21 (0.242) 16 (0.228) Reference
5A/5A or 6A/5A 66 (0,758) 54 (0,772) 0,931
(0.443 to 1.958)
5A/5A 19 (0.218) 20 (0.286) Reference
6A/6A or 6A/5A 68 (0.782) 50 (0.714) 1,432
(0.692 to 2.959)
6A/5A 47 (0.540) 34 (0.486) Reference
6A/6A or 5A/5A 40 (0,460) 36 (0,514) 0,8038
(0.428 to 1.510)
5A/5A or 6A/5A 66 (0,758) 54 (0,772) Reference
6A/6A 21 (0.242) 16 (0.228) 1,074
(0.511 to 2.258
6A/6A or 6A/5A 68 (0.782) 50 (0.714) Reference
5A/5A 19 (0.218) 20 (0.286) 0.698
(0.338 to 1.444)
MMP-9 Genotype T/T 1 (0.011) 0 (-)
C/T 27 (0.310) 20 (0.286)
C/C 59 (0.678) 50 (0.714)
T/T or T/C 28 (0.322) 20 (0.286) Reference
C/C 59 (0.678) 50 (0.714) 0.843
(0.424 to 1.675)
TC 27 (0.310) 20 (0.286) Reference
C/C or T/T 60 (0,690) 50 (0.714) 0,8889
(0.446 to 1.771)
C/C 59 (0.678) 50 (0.714) Reference
T/C or T/T 28 (0.322) 20 (0.286) 1,1864
0.5972 to 2.357
MMP-12 Genotype A/A 72 (0.828) 48 (0.686) Reference
A/G 14 (0.161) 22 (0.314) 0.424
(0.198 to 0.909)
G/G 1 (0.011) 0 (-)
A/G 14 (0.161) 22 (0.314) Reference
A/A or G/G 73 (0,839) 48 (0.686) 2,389
(1.115 to 5.13)
A/A 72 (0.828) 48 (0.686) ReferenceBMC Neurology 2009, 9:40 http://www.biomedcentral.com/1471-2377/9/40
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quencies of both the single nucleotide polymorphism and
the dinucleotide repeat length polymorphism of the
MMP-9 gene. Furthermore, concerning the latter poly-
morphism, its most active variant of 23 dinucleotide
repeats was more frequently found in the control group.
The frequencies of the single nucleotide polymorphisms
of the MMP-1, -3 and -12 genes which were not previously
investigated in sCAD patients were also comparable
between the patients and the control group.
The present study did not find a statistically significant
association between MMP polymorphisms and sCAD.
Due to the relatively small sample size of 70 patients,
these negative findings might however be due to insuffi-
cient power. As the present results are not sufficient to
make a definite statement about the genetic association
they need to be replicated in a larger group of patients.
This is however hardly possible in single centre studies
due to the overall low prevalence of sCAD and will need
future multicenter investigations.
Conclusion
The results of the present study do not support the
hypothesis that polymorphisms in MMP-1, -3, -9 and -12
leading to an increased expression rate of the correspond-
ing enzyme are susceptibility factors of sCAD. However,
this does not exclude a pathogenetic role for MMPs in
sCAD via secondary factors such as cytokines that are able
to induce these enzymes in cervical blood vessel walls.
Secondly, future multicenter studies including larger sam-
G/G or A/G 15 (0,172) 22 (0.314) 0,4545
(0.215 to 0.963)
G/G or A/G 15 (0,172) 22 (0.314) Reference
A/A 72 (0.828) 48 (0.686) 2,2
(1.038 to 4.662)
A/A or G/G 73 (0,839) 48 (0.686) Reference
A/G 14 (0.161) 22 (0.314) 0,4184
(0.195 to 0.897)
Table 1: Distribution of Genotypes and Alleles of all single nucleotide polymorphisms (Continued)
Table 2: Allele frequencies of the MMP-9 multiallelic (CA)n microsatellite polymorphism
Allele No. of CA Repeats Controls, No
(Frequency)
Patients, No
(Frequency)
Odds ratio
(95% confidence interval)
1 12 0 (-) 1 (0.007)
2 13 2 (0.011) 5 (0.036)
3 14 96 (0.551) 67 (0.478) 0.746
(0.477 to 1.117)
4 15 6 (0.034) 3 (0.021)
5 16 0 (-) 1 (0.007)
6 19) 2 (0.011) 4 (0.028)
7 20 1 (0.006) 5 (0.036)
8 21 19 (0.109) 23 (0.164) 1.604
(0.834 to 3.082)
9 22 26 (0.149) 20 (0.142) 0.949
(0.505 to 1.782)
10 23 19 (0.109) 10 (0.071) 0.628
(0.281 to 1.397)
11 24 3 (0.017) 1 (0.007)
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ple sizes are needed to verify or dismiss the lack of genetic
association of the MMP polymorphisms and sCAD found
in this pilot trial.
Abbreviations
sCAD: spontaneous cervical artery dissection; ECM: Extra-
cellular Matrix; MMP: Matrix Metalloproteinase.
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